(Q39474181)

English

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda

scientific article published on 14 September 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

phosphorylation

1 reference

based on heuristic

inferred from title

author name string

Maria Ait-Tihyaty

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Zakaria Rachid

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Catalin Mihalcioiu

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Bertrand J Jean-Claude

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

language of work or name

0 references

publication date

14 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

133

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

217-226

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

The catalytic mechanism and structure of thymidylate synthase

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Capecitabine: preclinical pharmacology studies

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

EGFR signal transactivation in cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Relevance of breast cancer cell lines as models for breast tumours: an update

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Comparison of alamar blue and MTT assays for high through-put screening

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1756-Z

21 January 2018

Identifiers

10.1007/S10549-011-1756-Z

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39474181&oldid=2202912156"